Categories
Lung Cancer

Lung Cancer Symptoms [Video]

@MedCram – Medical Lectures Explained CLEARLY @3D4Medical From Elsevier @3D4Medical From Elsevier @Dr.Education :Simplified Medical Explanations @Dr.Education :Simplified Medical Explanations @3D4Medical From Elsevier @Doctor Mike @Doc Tops @Doctor Youn @Doc Willie Ong @The X Factor USA @Ustad Rahat Fateh Ali Khan PME @Dr.G Bhanu Prakash Animated Medical Videos @Junglee Medicine @SickickMusic @Institute of Human Anatomy @Self Improvement Collage @Medical Research Community @INDIA MY JAAN @High Tech USA

Categories
Lung Cancer

1 Girl. 2 Interviews. 72 Hours. [Video]

I absolutely recommend checking out Ana Luisa ❤️ https://shop.analuisa.com/iz-hollyjane They create sustainable jewelry, their pieces start at $39, andyou get 10% off with my discount HOLLYJANE10 I know you will love them!#analuisany #analuisavip An autumn Dublin vlog, featuring three days of life at home, two job interviews, a sea swim, and lots of Cody the beagle. All against the backdrop of magical, gorgeous Dublin. _________________________________________________✨ MY AFFILIATE LINKS ✨These links are a FREE way for you to support my channel (seriously, it doesn’t cost you a thing), so if you are keen to purchase something you might have seen on my channel, and are in a position to support me, just find the item below and click on the link! I earn a very small commission from any purchases made via an affiliate link, so thank you in advance for your support 😇→ Sync your Google Calendar to Notion BOTH WAYS with Notion-Automation: https://bit.ly/hollyjane_NA→ My Study and Vlog Music from Epidemic Sound: https://bit.ly/holly_janeES→ Ana Luisa NY Jewellery https://shop.analuisa.com/so-hollyjane ✨ FAQ ✨What type of content do you make on this channel?I started off making Study With Me videos, then the channel evolved with some PhD Vlogs and Advice Videos, and then I started to document a little bit of my cancer journey… So now I make an unequal amount of all three 🙂 How old are you?I’m 31 in theory, but thanks to cancer/the pandemic putting life on hold for a couple of years, I genuinely only feel about… 26?! Where are you based?I’m Irish, and a PhD student at an Irish university but I am currently in MANHATTAN, BABY!!!!!What type of cancer are you getting treatment for?Stage IV oesophageal adenocarcinomaWhat drug are you on?An immunotherapy drug called Nivolumab (Opdivo)What type of PhD research are you carrying out?Historical research into records of children’s musical culture in IrelandWhich university are you carrying out your PhD research at?All Hallows, College, Dublin City University____________________________✨ Say hi on Instagram 🙂 or email enquiries.hollyjane@gmail.com Current subscriber count → 5,92000:00 Prelude00:29 Day 1. Pre-Interview Sea Swim.01:22 Meet Cody, Ana Luisa’s new brand ambassador02:30 Day 2. Pre-Interview Walkies03:48 Day 2. Post-Interview Talkies04:53 Day 3. Interview No. 2 in Dublin’s Fair City06:19 Postlude

Categories
Lung Cancer

Tips to Avoid Lung Cancer | 8 Ways to reduce risk of Lung Cancer | Secret to healthy life [Video]

Tips to Avoid Lung Cancer | 8 Ways to reduce risk of Lung Cancer | Secret to healthy lifeThis video shares tips on how to avoid lung cancer, including habits and food that can help you reduce risk of lung cancer.#tipstoavoidlungcancer #lungcancer Secret to healthy lifeVideo Tags:how to avoid lung cancer,how to prevent lung cancer,how to avoid lung cancer when smoking,lung cancer,lung cancer prevention,lung cancer treatment,lung cancer symptoms,lung cancer statistics,lung cancer search and rescue,how does smoking cause lung cancer,what percentage of smokers get lung cancer,how to avoid lung cancer after quitting smoking,8 Ways to reduce risk of Lung Cancer,Secret to healthy life,healthy lifestyle tips

Categories
Lung Cancer

2-step Dose-escalation to Establish Resistance in EGFR-TKI and MET-TKI | Protocol Preview [Video]

Watch the Full Video at https://www.jove.com/v/55967/establishing-dual-resistance-to-egfr-tki-met-tki-lung-adenocarcinoma?utm_source=youtube&utm_medium=social_global&utm_campaign=reseach-videos-2022.Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure – a 2 minute Preview of the Experimental ProtocolToshimitsu Yamaoka, Motoi Ohba, Satoru Arata, Tohru OhmoriShowa University, Institute of Molecular Oncology; Showa University, Center for Biotechnology;An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.Visit https://www.jove.com?utm_source=youtube&utm_medium=social_global&utm_campaign=reseach-videos-2022 to explore our entire library of 14,000+ videos of laboratory methods and science concepts.JoVE is the world-leading producer and provider of science videos with the mission to improve scientific research and education. Millions of scientists, educators, and students at 1500+ institutions worldwide, including schools like Harvard, MIT and Stanford benefit from using JoVE’s extensive library of 14,000+ videos in their research,education and teaching.Subscribe to our channel: https://www.youtube.com/c/JoVEJournalofVisualizedExperiments

Categories
Lung Cancer

TRICKY DUODENAL POLYPECTOMY USING DUODENOSCOPE [Video]

A 68 year old lady attended for a 2ww gastroscopy because of dyspepsia and weight loss. The procedure was performed by a nurse endosocpist and showed a 2cm sessile polyp at the junction of first and second parts of the duodenum. Biopsies from the polyp showed tubulovillous adenoma with low grade dysplasia. A CT scan of thorax, abdomen and pelvis was normal. She was referred for elective polypectomy (see video). The polyp was awkwardly located and it was necessary to use a duodenoscope. The duodenoscope had the advantage of being a side viewing scope and in addition the bridge helped to position the snare on to the scope.–Duodenal polyps are reported in 0.3–4.6% of patients attending for upper gastrointestinal endoscopy. Duodenal adenomas are mostly coincidental findings and most of these lesions are asymptomatic and seen in older patients (60 to 80 years of age). They can be divided into 3 subgroups: sporadically occurring duodenal adenomas or non-ampullary adenomas of the duodenum, duodenal adenomas of the papilla of Vater, and duodenal adenomas associated with genetic polyposis syndromes such as familial adenomatous polyposis (FAP) or Peutz Jeghers syndrome.Sporadic duodenal adenomas account for up to 7% of duodenal polyps biopsied during upper endoscopy. Sporadic duodenal adenomas are usually solitary, sessile, and they are predominantly found in the second part of the duodenum. Emerging evidence shows that duodenal adenomas share morphologic and molecular features with colorectal adenomas. Duodenal adenomas evolve to duodenal adenocarcinomas via similar mechanisms.In a study evaluating the risk of adenocarcinoma in nonampullary sporadic duodenal adenomas, Okada et al concluded that lesions with low-grade dysplasia and smaller than 20 mm have a low risk of progression to adenocarcinoma (4.7%) and some risk of progression to high-grade dysplasia (HGD), whereas adenomas that are larger than 20 mm, or have HGD, have a higher rate of progression to adenocarcinoma (approximately 54.5%).Because of this malignant potential, adenomas are therefore appropriately treated by endoscopic resection. However, the unique anatomical properties of the duodenum, namely its relatively thin and vascular walls, narrow luminal diameter and relationship to the ampulla and its associated pancreatic and biliary drainage, pose an increased degree of complexity for any endoscopic interventions in this area. The optimal approach for management of duodenal adenomas remains to be determined. The techniques for endoscopic resection of duodenal adenoma include snare polypectomy, endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), and argon plasma coagulation ablation.In a large Swiss series (Valli et al 2017) , a total of 78 patients underwent endoscopic polypectomy for non ampullary duodenal adenoma. End-of-treatment success with complete resection requiring a mean of 1.2 interventions was achieved in 91% (n = 71). Procedural haemorrhage occurred in 12.8% (n = 10), whereas delayed bleeding was noted in 9% (n = 7). Duodenal perforation was registered and successfully treated in 2 cases (2.6%). No adenoma recurrence was noted following primary complete adenoma resection after a mean follow-up time of 33 months. Acute post-polypectomy bleeding was statistically significantly associated with large polyp size (p = 0.003) and lack of endoscopic prophylaxis (p = 0.0008). Delayed post-polypectomy bleeding showed a trend in the occurrence of large polyps (p = 0.064), and was statistically significantly associated with familial cancer syndrome (p = 0.019) and advanced histopathology (p = 0.013).There are currently no well-accepted guidelines for the surveillance of sporadic adenomas, particularly after successful endoscopic resection, though many would advocate repeat upper endoscopy within 1 year to detect and treat residual or recurrent adenoma and to survey for other metachronous adenomas. REFERENCESsee first comment

Categories
Lung Cancer

LEAP-015: lenvatinib + pembrolizumab + mFOLFOX6 in advanced/met gastroesophageal adenocarcinoma [Video]

Kohei Shitara, National Cancer Center Hospital East, Kashiwa, Japan talks about the rationale and trial design of the Phase III LEAP-015 (NCT04662710) trial, randomized clinical study investigating the efficacy and safety of lenvatinib plus pembrolizumab plus mFOLFOX6 in patients with advanced gastroesophageal cancer. The trial consists of two parts; part one is treatment with lenvantinib in combination with pembrolizumab and chemotherapy; part two is randomization to receive lenvatinib plus pembrolizumab plus chemotherapy, or chemotherapy alone. Primary endpoints include overall-survival (OS) and progression-free survival (PFS). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.